Sinovac Biotech
40°01′52″N 116°18′01″E / 40.031°N 116.3003°E
Company type | Public | ||||||
---|---|---|---|---|---|---|---|
Nasdaq: SVA (American Depository Receipts) | |||||||
Founded | 1999 | ||||||
Founder | Yin Weidong[1] | ||||||
Headquarters | 39 Shang Di West Road, Haidian District, , China | ||||||
Number of employees | 910[2] | ||||||
Chinese name | |||||||
Simplified Chinese | 科兴控股生物技术有限公司 | ||||||
Traditional Chinese | 科興控股生物技術有限公司 | ||||||
Literal meaning | Kexing Holdings Biotechnology Co., Ltd. | ||||||
| |||||||
Website | sinovac.com |
Sinovac Biotech Ltd. (Chinese: 科兴控股生物技术有限公司, Nasdaq: SVA) is a Chinese biopharmaceutical company that focuses on the research, development, manufacture, and commercialization of vaccines that protect against human infectious diseases. The company is based in Haidian District, Beijing in China.[3] The company is listed on the NASDAQ but the exchange halted Sinovac's trading in February 2019 due to a proxy fight.[4][5] The company has faced bribery probes in China.[4]
Vaccines
Sinovac's commercialized vaccines include CoronaVac (COVID-19 vaccine), Inlive (Enterovirus 71 vaccine), Anflu (influenza vaccine), Healive (hepatitis A vaccine), varicella vaccine and mumps vaccine.[6]
COVID-19 vaccine development
CoronaVac is an inactivated virus COVID-19 vaccine developed by Sinovac.[7] It has been in Phase III clinical trials in Brazil,[8] Chile,[9] Indonesia,[10] Philippines,[11] and Turkey.[12]
It relies on traditional technology similar to BBIBP-CorV and BBV152, otherwise known as inactivated-virus COVID-19 vaccines in Phase III trials.[13] CoronaVac does not need to be frozen, and both the vaccine and raw material for formulating the new doses could be transported and refrigerated at 2–8 °C (36–46 °F), temperatures at which flu vaccines are kept.[14]
A real-world study of ten millions of Chileans who received CoronaVac found it 66% effective against symptomatic COVID-19, 88% against hospitalization, 90% against ICU admissions, and 86% against deaths.[15] In Brazil, after 75% of the population in Serrana, São Paulo received CoronaVac, preliminary results show deaths fell by 95%, hospitalizations by 86%, and symptomatic cases by 80%.[16][17] In Indonesia, real world data from 128,290 healthcare workers showed 94% protection against symptomatic infection by the vaccine, beating results in clinical trials.[18]
Phase III results from Turkey published in The Lancet showed an efficacy of 84% based on 10,218 participants in the trials.[19][20] Phase III results from Brazil previously showed 50.7% efficacy at preventing symptomatic infections and 83.7% effective in preventing mild cases needing treatment. Efficacy against symptomatic infections increased to 62.3% with an interval of 21 days or more between the doses.[21]
CoronaVac is being used in vaccination campaigns in various countries in Asia,[22][23][24] South America,[25][26][27] North America,[28][29][30] and Europe.[31][32][33] By April 2021, Sinovac had a production capacity of two billion doses a year[34] and had delivered 600 million total doses.[35] It is currently being manufactured at several facilities in China,[34] Brazil,[36] and Egypt.[37] On 1 June 2021, the World Health Organization (WHO) validated the vaccine for emergency use.[38][39][40] Sinovac has signed purchase agreements for 380 million doses from COVAX.[41]
See also
References
- ^ "China's Vaccine Front-Runner Aims to Beat Covid the Old-Fashioned Way". Bloomberg. 24 August 2020.
- ^ "Sinovac Biotech Ltd". bloomberg.com. Retrieved 4 May 2021.
- ^ "Home (English)". Sinovac. Retrieved 2021-03-06.
Add: No. 39 Shangdi Xi Road, Haidian District, Beijing, P.R.C. 100085
- Chinese address: "地址:北京市海淀区上地西路39号北大生物城" - ^ a b Dou, Eva (December 4, 2020). "As China nears a coronavirus vaccine, bribery cloud hangs over drugmaker Sinovac". The Washington Post. ISSN 0190-8286. Archived from the original on December 4, 2020. Retrieved 2020-12-06.
- ^ Levine, Matt (May 22, 2020). "A Vaccine With a Poison Pill". Bloomberg News. Archived from the original on June 21, 2020. Retrieved December 6, 2020.
- ^ "Vaccines". sinovac.com. Retrieved 1 September 2021.
- ^ Nidhi Parekh (22 July 2020). "CoronaVac: A COVID-19 Vaccine Made From Inactivated SARS-CoV-2 Virus". Retrieved 25 July 2020.
- ^ "New coronavirus vaccine trials start in Brazil". AP News. 21 July 2020. Retrieved 2020-10-07.
- ^ "Chile initiates clinical study for COVID-19 vaccine". Chile Reports. 4 August 2020. Retrieved 2020-10-07.
- ^ "248 volunteers have received Sinovac vaccine injections in Bandung". Antara News. 30 August 2020. Retrieved 2020-10-07.
- ^ "DOH eyes 5 hospitals for Sinovac vaccine Phase 3 clinical trial". PTV News. 16 September 2020. Retrieved 2020-10-07.
- ^ "Turkey begins phase three trials of Chinese Covid-19 vaccine". TRT World News. 1 September 2020. Retrieved 2020-10-07.
- ^ Zimmer, Carl; Corum, Jonathan; Wee, Sui-Lee. "Coronavirus Vaccine Tracker". The New York Times. ISSN 0362-4331. Retrieved 2021-02-12.
- ^ "CoronaVac: Doses will come from China on nine flights and can..." AlKhaleej Today (in Arabic). 2020-11-01. Retrieved 2021-02-12.
- ^ Jara A, Undurraga EA, González C, Paredes F, Fontecilla T, Jara G, et al. (July 2021). "Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile". The New England Journal of Medicine. 385 (10): 875–884. doi:10.1056/NEJMoa2107715. PMC 8279092. PMID 34233097. S2CID 235766915.
- ^ Savarese M (2021-06-01). "Sinovac vaccine restores a Brazilian city to near normal". CTV News. Retrieved 2021-06-02.
{{cite web}}
: CS1 maint: url-status (link) - ^ Pearson S (2021-05-31). "Brazil's Experiment to Vaccinate Town With Chinese CoronaVac Reduced Covid-19 Deaths by 95%". The Wall Street Journal. ISSN 0099-9660. Retrieved 2021-06-02.
- ^ "China Sinovac Shot Seen Highly Effective in Real World Study". MSN. 12 May 2021. Retrieved 12 May 2021.
- ^ Tanriover MD, Doğanay HL, Akova M, Güner HR, Azap A, Akhan S, et al. (8 July 2021). "Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey". The Lancet. 398 (10296): 213–222. doi:10.1016/S0140-6736(21)01429-X. ISSN 0140-6736. PMC 8266301. PMID 34246358. S2CID 235770533.
- ^ Evidence Assessment: Sinovac/CoronaVac COVID-19 vaccine (PDF) (Presentation). World Health Organization. 29 April 2021. Retrieved 10 July 2021.
- ^ Costa A (2021-04-11). "Estudo clínico que comprova maior eficácia da Coronavac é enviado para Lancet" [Clinical study proving greater efficacy of Coronavac is submitted to The Lancet]. CNN Brasil (in Portuguese). São Paulo. Retrieved 2021-04-12.
- ^ TARIGAN, EDNA; MILKO, VICTORIA (13 January 2021). "Indonesia starts mass COVID vaccinations over vast territory". Associated Press. Retrieved 15 January 2021.
- ^ "Thailand Kicks Off Covid-19 Vaccine Program With Sinovac Shots". Bloomberg.com. Retrieved 28 February 2021.
- ^ "China approves Sinovac vaccines for general public use". South China Morning Post. 6 February 2021. Retrieved 6 February 2021.
- ^ Rochabrun, Marcelo. "Brazil health ministry says plans to order 30 million more Coronavac doses | The Chronicle Herald". www.thechronicleherald.ca. Retrieved 26 February 2021.
{{cite web}}
: CS1 maint: url-status (link) - ^ Miranda, Natalia A. Ramos (28 January 2021). "Chile receives two million-dose first delivery of Sinovac COVID-19 vaccine". Reuters. Retrieved 30 January 2021.
- ^ "BNamericas - Uruguay prepares to launch COVID-19 vaccinat..." BNamericas.com. Retrieved 1 March 2021.
- ^ "Venustiano Carranza next up for Covid vaccination in Mexico City". Mexico News Daily. 2021-03-15. Retrieved 2021-03-16.
- ^ "Anticovid vaccines run out as Dominican Republic awaits arrival of more doses". Dominican Today. Retrieved 2021-03-10.
{{cite web}}
: CS1 maint: url-status (link) - ^ "Llegan a El Salvador un millón de dosis de la vacuna china CoronaVac contra el covid-19 de la farmacéutica Sinovac". Noticias de El Salvador - La Prensa Gráfica | Informate con la verdad (in European Spanish). Retrieved 2021-03-28.
- ^ "Turkey aims to vaccinate 60 percent of population: Minister – Turkey News". Hürriyet Daily News. Retrieved 12 February 2021.
- ^ "Vaccination with CoronaVac launched in Ukraine on April 13 – Health minister". www.unian.info. Retrieved 2021-04-15.
- ^ Semini, Llazar. "Albania starts mass COVID vaccinations before tourist season". ABC News. Retrieved 2021-03-28.
{{cite web}}
: CS1 maint: url-status (link) - ^ a b Liu, Roxanne (2021-04-02). "China Sinovac says it reached two billion doses annual capacity for COVID-19 vaccine". Reuters. Retrieved 2021-04-02.
{{cite news}}
: CS1 maint: url-status (link) - ^ Nebehay, Stephanie (2021-06-01). "WHO approves Sinovac COVID vaccine, the second Chinese-made dose listed". Reuters. Geneva. Retrieved 2021-06-01.
- ^ Mano A, Simões (10 December 2020). "Chinese vaccine draws demand across Latin America, say Brazilian officials". Reuters. Archived from the original on 10 December 2020. Retrieved 10 December 2020.
- ^ "Egypt to produce up to 80 million Sinovac vaccine doses annually". Arab News. 2021-04-08. Retrieved 2021-04-08.
- ^ Nebehay S (2021-06-01). "WHO approves Sinovac COVID vaccine, the second Chinese-made dose listed". Reuters. Geneva. Retrieved 2021-06-01.
- ^ "WHO recommendation Sinovac COVID-19 vaccine (Vero Cell [Inactivated]) – CoronaVac". World Health Organization (WHO). 1 May 2021. Retrieved 1 June 2021.
- ^ "WHO validates Sinovac COVID-19 vaccine for emergency use and issues interim policy recommendations". World Health Organization (WHO) (Press release). Retrieved 1 June 2021.
- ^ "Chinese drugmakers agree to supply more than half a billion vaccines to COVAX". Reuters. 2021-07-12. Retrieved 2021-07-13.
External links
- Official website
- Business data for Sinovac Biotech:
- Pharmaceutical companies of China
- Manufacturing companies based in Beijing
- Biotechnology companies of China
- Biopharmaceutical companies
- Vaccine producers
- Chinese companies established in 1999
- Chinese brands
- Biotechnology companies established in 1999
- Companies listed on the Nasdaq
- COVID-19
- Medical research
- Medical responses to the COVID-19 pandemic